LONDON and MONTREAL, Jan. 11, 2021 (GLOBE NEWSWIRE) -- DalCor Pharmaceuticals today announced the initiation of dal-COVID, a Phase 2 proof-of-concept study for dalcetrapib as a potential oral anti-viral treatment for COVID-19.
You need a license to cut-and-paste this copyrighted news content.nUse this link to purchase your paid subscription ($200/year for individuals and $1,000/year for companies of every size): https://endpts.com/subscribenAlready a paid subscriber? Sign in to Endpoints News to remove this message.nAstraZeneca vet Fouzia Laghrissi-Thode will be leading DalCor Pharmaceuticals through patient enrollment into its pivotal Phase III trial. The newly minted CEO has her work cut out for her — London-based DalCor is trying to prove that dalcetrapib, a CETP inhibitor Roche abandoned, has a strong cardio benefit for a subgroup of patients with a certain genotype by testing it in 6000 people. Laghrissi-Thode began tackling this field at Roche, where she was a franchise leader for several drugs.
The cardio sector continues to roll out new treatments to keep our blood pumping smoothly, cholesterol at bay and CV risk at a minimum. And as it does, marketers are striving to find a balance between brands already nestled in the market and the highly anticipated wave of cardio products ready to ink invitations to their launch parties.
Based on an analysis of data by an independent monitoring committee, Merck said it intends to continue the 30,000-patient REVEAL study of anacetrapib, with no changes, keeping it on course for completion in January 2017.
Canadians hope $250 mln trial can revive failed Roche heart drug
Market Place
Share Share
Share Share
